Precision Medicine in Oncology® | Specialty

Novel Therapies in Metastatic Melanoma

June 17th 2014

Strategies for the Detection of Recurrent Melanoma

June 17th 2014

Ipilimumab Side Effect Management in Melanoma

June 17th 2014

Adjuvant Treatment Selection in High-Risk Melanoma

June 17th 2014

Adjuvant Therapy for Stage III Melanoma

June 17th 2014

Role of Adjuvant Radiation Therapy in Melanoma

June 17th 2014

Molecular Testing in Resectable Melanoma

June 17th 2014

Lymph Node Management in Melanoma

June 17th 2014

Imaging and SLN Biopsy for Patients With Melanoma

June 17th 2014

Introduction: Surgical Excision of Melanoma

June 17th 2014

Leading Genome Researchers Confident That the Cancer Puzzle Will Be Solved

June 17th 2014

Gad Getz, PhD, MSc, focuses on cancer genome analysis, particularly cataloging all of the genomic events that occur during the development of cancer, in his laboratory at the Broad Institute at MIT and Harvard.

Dr. Kim Discusses Detecting EGFR and KRAS Mutations from Cell-Free Plasma DNA of NSCLC Patients

June 16th 2014

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of improved and complete enrichment co-amplification at lower denaturation temperature method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of patients with non-small cell lung cancer (NSCLC).

Targeted Therapy Challenges:More Cancer Genes Discovered, Mutational Burdens Defined

June 13th 2014

Even as technological advances make it possible to sequence DNA on a large scale at relatively lower costs and in shorter time-frames, emerging evidence from the world's top research laboratories suggests that scientists are still a long way from having a complete catalog of cancer genes.

USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History

June 11th 2014

Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations.

Continuing Afatinib Beyond Progression Improves PFS in Metastatic NSCLC

June 10th 2014

Continuing EGFR inhibition beyond progression with afatinib plus paclitaxel significantly improved PFS and ORR compared with chemotherapy alone in patients with heavily pretreated metastatic NSCLC.

Dr. Prat on the Differences Between EndoPredict and Prosigna

June 9th 2014

Aleix Prat, MD, PhD, medical oncologist, Vall D'Hebron Institute of Oncology, Barcelona, Spain, discusses the differences between EndoPredict and Prosigna.

Dr. Curran on the Effect of Clinical Trial Enrollment on NSCLC Patients

June 4th 2014

Walter J. Curran, Jr, MD, discusses a report that examined the effect of institutional clinical trial enrollment volume on survival of patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation.

Dr. Rizvi on Nivolumab Plus Erlotinib in Patients with EGFR MT NSCLC

June 1st 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses the safety and response with plus erlotinib in patients with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC).

Dr. Hussain on ETS Gene Fusions as a Predictive Biomarker in Prostate Cancer

May 31st 2014

Maha Hussain, MD, from the University of Michigan Comprehensive Cancer Center, discusses the possibility of ETS gene fusions acting as a predictive biomarker for prostate cancer.

WellPoint's Enhanced Payment Plan Encourages Following Treatment Protocols

May 28th 2014

A new reimbursement program initiated by WellPoint, Inc., looks to pay oncologists an additional $350 a month for each patient who is enrolled in and follows one of the insurer's recommended cancer treatment regimens